Home > Strength of evidence - Drug Class...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

McDonagh MS, Peterson K, Thakurta S, et al. Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Dec.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Appendix EStrength of evidence

Table 1Methylphenidate OROS compared with immediate-release methylphenidate

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; Number of SubjectsRisk of Bias (Design/ Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
Response
No dataNANANANANAInsufficient
Maintenance of response (much or very much improved on the Clinical Global Impression Scale)
1; N=53Medium (RCT/Fair)NADirectImprecise63% vs 58%, P=0.8Low
Withdrawals due to adverse events
No dataNANANANANAInsufficient
Decreased appetite
1; N=53Medium (RCT/Fair)NADirectImprecise27% vs 11%, P not reportedInsufficient
Sleep disturbance
No dataNANANANANAInsufficient

Abbreviations: NA, not applicable; RCT, randomized controlled trial.

Table 2Immediate-release guanfacine compared with immediate-release dextroamphetamine

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; Number of SubjectsRisk of Bias (Design/ Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
Response
No dataNANANANANAInsufficient
ADHD Symptoms: mean total symptom score of the DSM-IV ADHD Behavior Checklist for Adults
1, N=17Medium (RCT/Fair)NADirectImprecise23.3 points vs. 24.2 pointsLow
Withdrawals due to adverse events
No dataNANANANANAInsufficient
Decreased appetite
No dataNANANANANAInsufficient
Sleep disturbance
No dataNANANANANAInsufficient

Abbreviations: NA, not applicable; RCT, randomized controlled trial.

Table 3Modafinil compared with immediate-release dextroamphetamine

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; Number of SubjectsRisk of Bias (Design/ Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
Response: 30% or greater mean improvement in ADHD Rating Scale total scores
1; N=22Medium (RCT/Fair)NADirectImprecise48% vs 48%Low
Withdrawals due to adverse events
1; N=22Medium (RCT/Fair)NADirectImprecise0 vs 0Low
Decreased appetite
1; N=22Medium (RCT/Fair)NADirectImprecise24% vs 19%, P=NSLow
Sleep disturbance
1; N=22Medium (RCT/Fair)NADirectImprecise38% vs 19%, P=NSLow

Abbreviations: NA, not applicable; NS, not significant; RCT, randomized controlled trial.

Copyright © 2011 by Oregon Health & Science University.
Cover of Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report [Internet].
McDonagh MS, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Dec.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...